Investors responded to Moderna and Merck’s melanoma mRNA vaccine Phase III results not just in the developers’ stocks but also across sequencing companies tied to personalized oncology workflows, according to StockWatch coverage. The report highlighted gains for Illumina, Pacific Biosciences, and Oxford Nanopore after the INTerpath-001 data, citing the therapy’s dependence on individualized tumor mutation identification. It also noted additional company-specific drivers for sequencing vendors. The net effect was a reminder that clinical wins for personalized therapies can transmit quickly into upstream enabling technology markets.